Enterocolitis: An adverse event in refractory epilepsy patients treated with levetiracetam?

Seizure

Volumn 13, Issue 2, 2004, Pages 76-81

  Bosman, Tommy ^a   Vonck, Kristl ^a   Claeys, Pieter ^a   Van Vlierberghe, Hans ^a   De Clercq, Matti ^a   De Reuck, Jacques ^a   Boon, Paul ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Adverse events; Colitis; Levetiracetam; Refractory epilepsy

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ETIRACETAM; LAMOTRIGINE; NONSTEROID ANTIINFLAMMATORY AGENT; PIRACETAM; SALICYLIC ACID DERIVATIVE; SERTRALINE; TIAGABINE; TOPIRAMATE; VALPROIC ACID;

ABDOMINAL PAIN; ADULT; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COLITIS; COLONOSCOPY; COMPLEX PARTIAL SEIZURE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG ERUPTION; DRUG INHIBITION; DRUG TOXICITY; ELECTROENCEPHALOGRAM; ENTEROCOLITIS; EPILEPSY; ERYTHROCYTE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOCHEZIA; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY REACTION; MALE; MUSCLE FATIGUE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SOMNOLENCE; STOMACH PAIN; TEMPORAL LOBE EPILEPSY; TEMPORAL LOBECTOMY; THROMBOCYTE; WADA TEST; WEIGHT REDUCTION;

EID: 1242329251     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2003.09.010     Document Type: Article

References (47)

1. Hauser WA, Hesdorffer DH. Epilepsy: frequency, causes and consequences. New York: Demos Press; 1990. p. 1-51.
2. Kwan, P. and Brodie, M. J. Early identification of refractory epilepsy. N Engl J Med 2000; 342 (5): 314-319.
3. Begley, C. E. et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia 2000; 41 (3): 342-351.
4. McAuley, J. W. et al. Newer therapies in the drug treatment of epilepsy. Ann Pharmacother 2002; 36 (1): 119-129.
5. Hovinga, C. A. Novel anticonvulsant medications in development. Exp Opin Investig Drugs 2002; 11 (10): 1387-1406.
6. Genton, P. and Van Vleymen, B. Piracetam and LEV: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2000; 2 (2): 99-105.
7. Loscher, W. and Richter, A. Piracetam and LEV, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia. Eur J Pharmacol 2000; 391 (3): 251-254.
8. Loscher, W., Reissmuller, E. and Ebert, U. Anticonvulsant efficacy of gabapentin and LEV in phenytoin-resistant kindled rats. Epilepsy Res 2000; 40 (1): 63-77.
9. Loscher, W. and Honack, D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993; 232 (2/3): 147-158.
10. Gower, A. J. et al. Effects of LEV, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 1995; 22 (3): 207-213.
11. Gower, A. J. et al. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992; 222 (2/3): 193-203.
12. Klitgaard, H. et al. Evidence for a unique profile of LEV in rodent models of seizures and epilepsy. Eur J Pharmacol 1998; 353 (2/3): 191-206.
13. Georg Margineanu, D. and Klitgaard, H. Inhibition of neuronal hypersynchrony in vitro differentiates LEV from classical antiepileptic drugs. Pharmacol Res 2000; 42 (4): 281-285.
14. Noyer, M. et al. The novel antiepileptic drug LEV (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995; 286 (2): 137-146.
15. Loscher, W., Honack, D. and Rundfeldt, C. Antiepileptogenic effects of the novel anticonvulsant LEV (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998; 284 (2): 474-479.
16. Patsalos, P. N. Pharmacokinetic profile of LEV: toward ideal characteristics. Pharmacol Ther 2000; 85 (2): 77-85.
17. Cereghino, J. J. et al. LEV for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55 (2): 236-242.
18. Betts, T., Waegemans, T. and Crawford, P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of LEV, 2000 mg daily and 4000 mg daily, without fitration in patients with refractory epilepsy. Seizure 2000; 9 (2): 80-87.
19. van Rijckevorsel, K. and Boon, P. A. The 'number needed to treat' with LEV (LEV): comparison with the other new antiepileptic drugs (AEDs). Seizure 2001; 10 (3): 235-236.
20. Bazil, C. W. et al. LEV may be more effective for late-onset partial epilepsy. Arch Neurol 2002; 59 (12): 1905-1908.
21. Motamedi, M. et al. LEV efficacy in refractory partial-onset seizures, especially after failed epilepsy surgery. Epilepsia 2003; 44 (2): 211-214.
22. Eccher M, et al. Possible relationship of LEV therapy to hemorrhagic complications in epilepsy surgery. Seattle: American Epilepsy Society; 2002.
23. Shorvon, S. D. et al. Multicentre double-blind, randomized, placebo-controlled trial of LEV as add-on therapy in patients with refractory partial seizures. European LEV Study Group. Epilepsia 2000; 41 (9): 1179-1186.
24. French, J., Edrich, P. and Cramer, J. A. A systematic review of the safety profile of LEV: a new antiepileptic drug. Epilepsy Res 2001; 47 (1/2): 77-90.
25. Kaur, S. et al. Anticonvulsant hypersensitivity syndrome. Pediatr Dermatol 2002; 19 (2): 142-145.
26. Klassen, B. D. and Sadler, R. M. Induction of hypersensitivity to a previously tolerated antiepileptic drug by a second antiepileptic drug. Epilepsia 2001; 42 (3): 433-435.
27. Eland, I. A. et al. Colitis may be part of the antiepileptic drug hypersensitivity syndrome. Epilepsia 1999; 40 (12): 1780-1783.
28. Benedetti, M. S. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 2000; 14 (4): 301-319.
29. Browne, T. R. et al. Absence of pharmacokinetic drug interaction of LEV with phenytoin in patients with epilepsy determined by new technique. J Clin Pharmacol 2000; 40 (6): 590-595.
30. Nicolas, J. M. et al. In vitro evaluation of potential drug interactions with LEV, a new antiepileptic agent. Drug Metab Dispos 1999; 27 (2): 250-254.
31. Nash, E. M. and Sangha, K. S. LEV. Am J Health Syst Pharm 2001; 58 (13): 1195-1199.
32. Tysk, C. Drug-induced enterocolitis. Important differential diagnosis in the investigation of diarrhea and intestinal hemorrhage. Lakartidningen 2000; 97 (21): 2606-2610.
33. Mahajan, L., Wyllie, R. and Goldblum, J. Lymphocytic colitis in a pediatric patient: a possible adverse reaction to carbamazepine. Am J Gastroenterol 1997; 92 (11): 2126-2127.
34. Sisodiya, S. M., Sander, J. W. and Patsalos, P. N. Carbamazepine toxicity during combination therapy with LEV: a pharmacodynamic interaction. Epilepsy Res 2002; 48 (3): 217-219.
35. Besag, F. M. et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39 (2): 183-187.
36. Blackburn, S. C. et al. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 1998; 18 (6): 1277-1283.
37. Acharya, S. and Bussel, J. B. Haematologic toxicity of sodium valproate. J Pediatr Hematol/Oncol 2000; 22 (1): 62-65.
38. Serdaroglu, G. et al. Coagulation abnormalities and acquired von Willebrand's disease type 1 in children receiving valproic acid. J Child Neurol 2002; 17 (1): 41-43.
39. Zeller, J. A. et al. Influence of valproate monotherapy on platelet activation and haematologic values. Epilepsia 1999; 40 (2): 186-189.
40. Ishikita, T. et al. Carbamazepine-induced thrombocytopenia defined by a challenge test. Am J Hematol 1999; 62 (1): 52-55.
41. Alehan, F. K., Russell, E. C. and Pellock, J. M. Phenytoin-associated thrombocytopenia in a toddler. J Child Neurol 1999; 14 (2): 130-131.
42. Kaufman, D. W. et al. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997; 38 (12): 1265-1269.
43. Hartmann, H., Schumacher, U. and Seeck, M. Worsening of an immune thrombocytopenia during monotherapy with LEV. Aktuelle Neurol 2002; 29 (9): 467-468.
44. Muller, W. E. et al. Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem Pharmacol 1997; 53 (2): 135-140.
45. Nalbandian, R. M. et al. Diminished adherence of sickle erythrocytes to cultured vascular endothelium by piracetam. Am J Hematol 1983; 15 (2): 147-151.
46. Stockmans, F. et al. Inhibitory effect of piracetam on platelet-rich thrombus formation in an animal model. Thromb Haemost 1998; 79 (1): 222-227.
47. Lukyanetz, E. A., Shkryl, V. M. and Kostyuk, P. G. Selective blockade of N-type calcium channels by LEV. Epilepsia 2002; 43 (1): 9-18.